SLC6A1 and schizophrenia: GAT1-addressingradioligands would be especially beneficial for patients with temporallobe epilepsy, as several lines of evidence suggest these patientshave reduced GAT expression.6−10 Moreover, the effect of GAT1-modulating drugs has also been studiedon anxiety disorders, depression, sleep apnea, and schizophrenia andhas shown promising results in preclinical studies.11 As such, noninvasive imaging of GAT1 could help to moreprecisely understand the role of GAT1 in these disorders as well.